IP Library › Granted Patent US 12,234,264
Granted Patent B2
US 12,234,264 · App. 17/450,348 · Granted Feb 25, 2025

Stabilized soluble pre-fusion RSV F proteins

Inventors: Anders Krarup (Glostrup, DK); Johannes Petrus Maria Langedijk (Amsterdam, NL)
Assignee: Janssen Vaccines & Prevention B.V.
C07K14/135A61K39/12A61P31/14C07K14/005C07K16/1027C12N15/62A61K2039/55505A61K2039/57C12N2760/18522C12N2760/18534
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,234,264
App. No.
17/450,348
Granted
Feb 25, 2025
Kind
B2
Abstract

Stable pre-fusion respiratory syncytial virus (RSV) F proteins (or fragment thereof) are described. Compositions containing the proteins and uses of the compositions for the prevention and/or treatment of RSV infection are also described.

Claims (8)

1. A recombinant polypeptide comprising F1 and F2 domains of a variant pre-fusion respiratory syncytial virus (RSV) Fusion (F) protein and a fibritin trimerization domain, wherein the recombinant polypeptide comprises the amino acid sequence of SEQ ID NO: 1.

2. A nucleic acid molecule encoding the recombinant polypeptide of claim 1 .

3. A vector comprising a polynucleotide sequence encoding the recombinant polypeptide of claim 1 .

4. A host cell comprising a nucleic acid molecule encoding the recombinant polypeptide of claim 1 .

5. A composition comprising the recombinant polypeptide of claim 1 .

6. A composition comprising a nucleic acid molecule encoding the recombinant polypeptide of claim 1 .

7. A method of inducing an immune response against an RSV F protein in a subject in need thereof, the method comprising administering to the subject the composition according to claim 5 .

8. A method of inducing an immune response against an RSV F protein in a subject in need thereof, the method comprising administering to the subject the composition according to claim 6 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2021
From: KRARUP, ANDERS; LANGEDIJK, JOHANNES PETRUS MARIA
To: JANSSEN VACCINES & PREVENTION B.V.
Reel/Frame 057807/0646 →
Priority Claims (1)
EP 16163810 · Apr 5, 2016 · regional
Continuity (2)
Continuation 16091344
Related Publication 20220089652A1 · Mar 24, 2022
References Cited (228)
US 4235877A · Fullerton · 1980 [cited by applicant]
US 4372945A · Likhite · 1983 [cited by applicant]
US 4474757A · Arnon et al. · 1984 [cited by applicant]
US 5057540A · Kensil et al. · 1991 [cited by applicant]
US 5122458A · Post et al. · 1992 [cited by applicant]
US 5385839A · Stinski · 1995 [cited by applicant]
US 5559099A · Wickham et al. · 1996 [cited by applicant]
US 5837511A · Falck-Pedersen et al. · 1998 [cited by applicant]
US 5837520A · Shabram et al. · 1998 [cited by applicant]
US 5846782A · Wickham et al. · 1998 [cited by applicant]
US 5851806A · Kovesdi et al. · 1998 [cited by applicant]
US 5851808A · Elledge · 1998 [cited by applicant]
US 5891690A · Massie · 1999 [cited by applicant]
US 5965541A · Wickham et al. · 1999 [cited by applicant]
US 5981225A · Kochanek et al. · 1999 [cited by applicant]
US 5994106A · Kovesdi et al. · 1999 [cited by applicant]
US 5994108A · Gaynor · 1999 [cited by applicant]
US 5994128A · Fallaux et al. · 1999 [cited by applicant]
US 6020191A · Scaria et al. · 2000 [cited by applicant]
US 6040174A · Imler et al. · 2000 [cited by applicant]
US 6083716A · Wilson et al. · 2000 [cited by applicant]
US 6113913A · Brough et al. · 2000 [cited by applicant]
US 6225289B1 · Kovesdi et al. · 2001 [cited by applicant]
US 6261823B1 · Tang et al. · 2001 [cited by applicant]
US 6281823B1 · Gross, Jr. · 2001 [cited by applicant]
US 6485958B2 · Blanche et al. · 2002 [cited by applicant]
US 7270811B2 · Bout et al. · 2007 [cited by applicant]
US 7326555B2 · Konz, Jr. et al. · 2008 [cited by applicant]
US 8225289B2 · Burton · 2012 [cited by applicant]
US 8485958B2 · Nash · 2013 [cited by applicant]
US 8568719B2 · Williamson · 2013 [cited by applicant]
US 8772256B2 · Graham et al. · 2014 [cited by applicant]
US 8772258B2 · Kirkpatrick · 2014 [cited by applicant]
US 8932607B2 · Custers et al. · 2015 [cited by applicant]
US 10294279B2 · Langedijk · 2019 [cited by applicant]
US 10729757B2 · Langedijk · 2020 [cited by examiner]
US 10899800B2 · Langedijk · 2021 [cited by examiner]
US 10953087B2 · Langedijk · 2021 [cited by applicant]
US 11034731B2 · Langedijk · 2021 [cited by applicant]
US 11155583B2 · Krarup · 2021 [cited by examiner]
US 11229692B2 · Godeaux · 2022 [cited by applicant]
US 11229694B2 · Langedijk · 2022 [cited by applicant]
US 11229695B2 · Widjojoatmodjo · 2022 [cited by applicant]
US 11338031B2 · Langedijk · 2022 [cited by applicant]
US 20100261155A1 · Peeples · 2010 [cited by applicant]
US 20110305727A1 · Swanson et al. · 2011 [cited by applicant]
US 20120164176A1 · Swanson et al. · 2012 [cited by applicant]
US 20120315270A1 · McLellan et al. · 2012 [cited by applicant]
US 20130177573A1 · Williamson et al. · 2013 [cited by applicant]
US 20140073032A1 · Custers et al. · 2014 [cited by applicant]
US 20140248314A1 · Swanson et al. · 2014 [cited by applicant]
US 20140271699A1 · Kwong et al. · 2014 [cited by applicant]
US 20140271899A1 · Leiter · 2014 [cited by applicant]
US 20160102123A1 · Langedijk et al. · 2016 [cited by applicant]
US 20160145321A1 · Wadia et al. · 2016 [cited by applicant]
US 20160145322A1 · Wadia et al. · 2016 [cited by applicant]
US 20160176932A1 · Langedijk et al. · 2016 [cited by applicant]
US 20170182151A1 · Che · 2017 [cited by applicant]
US 20180102123A1 · Tisch · 2018 [cited by applicant]
US 20180145321A1 · Yamauchi · 2018 [cited by applicant]
US 20180145322A1 · Choi · 2018 [cited by applicant]
US 20200061181A1 · Godeaux · 2020 [cited by applicant]
US 20200197509A1 · Widjojoatmodjo · 2020 [cited by applicant]
US 20200360506A1 · Langedijk · 2020 [cited by applicant]
US 20210101940A1 · Langedijk · 2021 [cited by applicant]
US 20210205440A1 · Langedijk · 2021 [cited by applicant]
US 20210284698A1 · Langedijk · 2021 [cited by applicant]
US 20220017574A1 · Langedijk · 2022 [cited by applicant]
US 20220125910A1 · Godeaux · 2022 [cited by applicant]
US 20220125912A1 · Langedijk · 2022 [cited by applicant]
US 20220133878A1 · Widjojoatmodjo · 2022 [cited by applicant]
US 20220193219A1 · Callendret · 2022 [cited by applicant]
US 20220204567A1 · Brandenburg · 2022 [cited by applicant]
US 20220273787A1 · Callendret · 2022 [cited by applicant]
US 20220288186A1 · Langedijk · 2022 [cited by applicant]
EP 0853660A1 · 1998 [cited by applicant]
EP 1230354 · 2002 [cited by applicant]
EP 3464331 · 2019 [cited by applicant]
JP 2015512380 · 2015 [cited by applicant]
JP 2015171378 · 2015 [cited by applicant]
JP 2018527897 · 2018 [cited by applicant]
KR 20140138765 · 2014 [cited by applicant]
WO 9003184A1 · 1990 [cited by applicant]
WO 9014837A1 · 1990 [cited by applicant]
WO 9609378A1 · 1996 [cited by applicant]
WO 9611711A1 · 1996 [cited by applicant]
WO 9822588A2 · 1998 [cited by applicant]
WO 9839411A1 · 1998 [cited by applicant]
WO 9912568A1 · 1999 [cited by applicant]
WO 9941416A2 · 1999 [cited by applicant]
WO 200029024A1 · 2000 [cited by applicant]
WO 200032754A1 · 2000 [cited by applicant]
WO 200070071A1 · 2000 [cited by applicant]
WO 200166137A1 · 2001 [cited by applicant]
WO 2001085984A1 · 2001 [cited by applicant]
WO 200240665A2 · 2002 [cited by applicant]
WO 03040178A1 · 2003 [cited by applicant]
WO 2003049763A1 · 2003 [cited by applicant]
WO 2003061708A1 · 2003 [cited by applicant]
WO 2003078592A2 · 2003 [cited by applicant]
WO 2003104467A1 · 2003 [cited by applicant]
WO 2004001032A2 · 2003 [cited by applicant]
WO 2004004762A1 · 2004 [cited by applicant]
WO 2004020971A2 · 2004 [cited by applicant]
WO 2005002620A1 · 2005 [cited by applicant]
WO 2005071093A2 · 2005 [cited by applicant]
WO 2005080556A2 · 2005 [cited by applicant]
WO 2006108707A1 · 2006 [cited by applicant]
WO 2007104792A2 · 2007 [cited by applicant]
WO 2007110409A1 · 2007 [cited by applicant]
WO 2008154456A2 · 2008 [cited by applicant]
WO 200911713A1 · 2009 [cited by applicant]
WO 2009011713 · 2009 [cited by applicant]
WO 2009079796A1 · 2009 [cited by applicant]
WO 2009106580A1 · 2009 [cited by applicant]
WO 2010060719A1 · 2010 [cited by applicant]
WO 2010080719A1 · 2010 [cited by applicant]
WO 2010086189A2 · 2010 [cited by applicant]
WO 2010149743A2 · 2010 [cited by applicant]
WO 2010149745A1 · 2010 [cited by applicant]
WO 2011008974A2 · 2011 [cited by applicant]
WO 2011020079A1 · 2011 [cited by applicant]
WO 2011045378A1 · 2011 [cited by applicant]
WO 2011045381A1 · 2011 [cited by applicant]
WO 2011050168A2 · 2011 [cited by applicant]
WO 2011098592A1 · 2011 [cited by applicant]
WO 2012006596A2 · 2012 [cited by applicant]
WO 2012158613A1 · 2012 [cited by applicant]
WO 2013139911A1 · 2013 [cited by applicant]
WO 2013139916A1 · 2013 [cited by applicant]
WO 2013135615A1 · 2013 [cited by applicant]
WO 2014005643A1 · 2014 [cited by applicant]
WO 2014077096 · 2014 [cited by applicant]
WO 2014152534A1 · 2014 [cited by applicant]
WO 2014160463A1 · 2014 [cited by applicant]
WO WO2014174018A1 · 2014 [cited by applicant]
WO WO2014202570A1 · 2014 [cited by examiner]
WO 2015013551A1 · 2015 [cited by applicant]
WO 2015040002A1 · 2015 [cited by applicant]
WO 2015189425 · 2015 [cited by applicant]
WO 2016040556 · 2016 [cited by applicant]
WO 2017005844 · 2017 [cited by applicant]
WO 2017005848 · 2017 [cited by applicant]
WO 2017075125A1 · 2017 [cited by applicant]
WO 2017172890A1 · 2017 [cited by applicant]
WO 2017174564A1 · 2017 [cited by applicant]
WO 2017207480 · 2017 [cited by applicant]
WO 2021198413 · 2021 [cited by applicant]
WO 2022002894 · 2022 [cited by applicant]
Hotard et al., “Identification of Residues in the Human Respiratory Syncytial Virus Fusion Protein That Modulate Fusion Activity and Pathogenesis”, Journal of Virology, Jan. 2015, vol. 89, No. 1, pp. 512-522. [cited by applicant]
Comparison to Sequence 16, U.S. Appl. No. 12/517,194; U.S. Pat. No. 8,772,256 (Year: 2014) 4 pages. [cited by applicant]
International Search Report and Written Opinion issued in PCT/EP2017/062875, dated Aug. 14, 2017, 10 pages. [cited by applicant]
McClellan et al., Science vol. 340, p. 1114, (Year: 2013). [cited by applicant]
McClellan et al (Science vol. 342, p. 592ff, 2013 (Year: 2013). [cited by applicant]
Gilman et al., “Rapid profiling of RSV antibody repertories from the memory B cells of naturally infected adult donors”, Science Immunology, 11 pages, Dec. 2016. [cited by applicant]
Openshaw et al., “Protective and Harmful Immunity to RSV Infection”, Annu Rev. Immunol, vol. 35, pp. 501-532, 2017. [cited by applicant]
Janssen Vaccines & Prevention B.V.: A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV. preF One Year Apart in Adults Aged 60 Years and Older in Stable Health, Oct. 2016, ret… [cited by applicant]
Int'l Search Report and Written Opinion issued Dec. 17, 2018 in Int'l Application No. PCT/EP2018/074710. [cited by applicant]
Bangari et al., “Development of nonhuman adenoviruses as vaccine vectors”, Vaccine, 24(7), pp. 849-862, 2006. [cited by applicant]
Cohen et al., “Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor”, Journal of General Virology, 83, pp. 151-155, 2002. [cited by applicant]
Farina et al., “Replication-Defective Vector Based on a Chimpanzee Adenovirus”, Journal of Virology, vol. 75, No. 23, pp. 11603-11613, Dec. 2001. [cited by applicant]
Kobinger et al., “Chimpanzee adenovirus vaccine protects against Zaire Ebola Virus”, Science Direct, Virology, 346, pp. 394-401, 2006. [cited by applicant]
Lasaro et al., “New Insights on Adenovirus as Vaccine Vectors”, Molecular Therapy, vol. 17, No. 8, pp. 1333-1339, Aug. 2009. [cited by applicant]
Tatsis et al., “A CD46-binding Chimpanzee Adenovirus Vector as a Vaccine Carrier”, American Society of Gene Therapy, vol. 15, No. 3, pp. 608-617, Mar. 2007. [cited by applicant]
Widjojatomodjo et al., “Recombianant Low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats”, V… [cited by applicant]
Green et al., “Safety and Immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV): protocol for an ope… [cited by applicant]
Grunwald et al., “Novel Vaccine Regimen Elicits Strong Airway Immune Responses and Control of Respiratory Syncytial Virus in Nonhuman Primates”, Journal of Virology, vol. 88, No. 8, pp. 3997-4007, Apr. 2014. [cited by applicant]
Int'l Search Report and Written Opinion issued Sep. 8, 2018 in Int'l Application No. PCT/EP2018/062604. [cited by applicant]
Neuzil, “Progress toward a Respiratory Syncytial Virus Vaccine”, Clinical and Vaccine Immunology, vol. 23, pp. 186-188, 2016. [cited by applicant]
McLellan et al., “Structural Basis of Respiratory Syncytial Virus Neutralization by Motavizumab,” Nature Structural & Molecular Biology, vol. 17, pp. 248-250 (2010). [cited by applicant]
McLellan et al., “Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody,” Science, vol. 340, pp. 1113-1117 (2013). [cited by applicant]
McLellan et al., “Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus,” Science, vol. 342, pp. 592-598 (2013). [cited by applicant]
Swanson et al., “Structural Basis for Immunization with Postfusion Respiratory Syncytial Virus Fusion F Glycoprotein (RSV F) to Elicit High Neutralizing Antibody Titers,” PNAS, vol. 108, pp. 9619-9624 (2011). [cited by applicant]
Letarov et al., “The Carboxy-Terminal Domain Initiates Trimerization of Bacteriophage T4 Fibritin,” Biochemistry (Moscow), vol. 64, No. 7, pp. 817-823 (1999). [cited by applicant]
Guthe et al., “Very Fast Folding and Association of a Trimerization Domain from Bacteriophage T4 Fibritin,” J. Mol. Biol., vol. 337, pp. 905-915 (2004). [cited by applicant]
“Database UniProt Accession W8CJC7,” http://ibis.internal.epo.org/exam/dbfetch.jsp?id=UNIPROT:W8CJC7, Download date: Aug. 12, 2015, 1 page. [cited by applicant]
Widjaja et al., “Recombinant soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics,” PLOS One, 20 pages,… [cited by applicant]
Written Opinion issued Oct. 10, 2016 in Int'l Application No. PCT/EP2016/066104. [cited by applicant]
Int'l Search Report issued Oct. 10, 2016 in Int'l Application No. PCT/EP2016/066104. [cited by applicant]
Written Opinion issued Oct. 12, 2016 in Int'l Application No. PCT/EP2016/066098. [cited by applicant]
Int'l Search Report issued Oct. 12, 2016 in Int'l Application No. PCT/EP2016/066098. [cited by applicant]
Suzuki et al., “An Isoleucine Zipper Peptide Forms a Native-like Triple Stranded Coiled Coil in Solution,” Protein Engineering, vol. 11, No. 11, pp. 1051-1055 (1998). [cited by applicant]
Dames et al., “NMR Structure of a Parallel Homotrimeric Coiled Coil,” Nature Structural Biology, vol. 5, No. 8, pp. 687-691 (Aug. 1998). [cited by applicant]
Calder et al., “Electron Microscopy Of The Human Respiratory Syncytial Virus Fusion Protein And Complexes That It Forms With Monoclonal Antibodies,” Virology, vol. 271, pp. 122-131 (2000). [cited by applicant]
Harbury et al., “A Switch Between Two- , Three- , and Four-Stranded Coiled Coils in GCN4 Leucine Zipper Mutants,” Science, vol. 262, pp. 1401-1407. [cited by applicant]
O'Shea et al., “Evidence That The Leucine Zipper Is A Coiled Coil,” Science, vol. 243, pp. 538-542 (Jan. 27, 1989). [cited by applicant]
Database EMBL, Aug. 28, 1995, Human respiratory syncytial virus, strain RSB89-1734, fusion protein (F) mRNA, complete CDS, XP002729919. [cited by applicant]
Int'l Search Report and Written Opinion issued Oct. 9, 2014 in Int'l Application No. PCT/EP2014/062655. [cited by applicant]
Int'l Search Report and Written Opinion issued Aug. 12, 2014 in Int'l Application No. PCT/EP2014/058353. [cited by applicant]
Magro et al., “Neutralizing Antibodies Against the Preactive Form of Respiratory Syncytial Virus Protein Offer Unique Possibilities for Clinical Intervention,” PNAS, vol. 109, No. 8, pp. 3089-3094 (Feb. 21, 2012). [cited by applicant]
Yin et al., “Structure of the Parainfluenza Virus 5 F Protein in its Metastable, Prefusion Conformation,” Nature, vol. 439, pp. 38-44 (Jan. 5, 2006). [cited by applicant]
Ngwuta et al, “Prefusion F-Specific Antibodies Determine the Magnitude of RSV Neutralizing Activity in Human Sera,” Science Translational Medicine, vol. 7, No. 309, pp. 1-9 (2015). [cited by applicant]
Int'l Search Report and Written Opinion issued Jun. 12, 2017 in Int'l Application No. PCT/EP2017/057962. [cited by applicant]
Abbink et al, “Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D,” Journal of Virology, vol. 81, No. 9, pp. 4654-4663 (May 2007). [cited by applicant]
Abrahamsen et al, “Construction of an Adenovirus Type 7a E1A-Vector,” Journal of Virology, vol. 71, No. 11, pp. 8946-8951 (Nov. 1997). [cited by applicant]
Altaras et al, “Production and Formulation of Adenovirus Vectors,” Advances in Biochemical Engineering /Biotechnology, vol. 99, pp. 193-260 (2005). [cited by applicant]
Brough et al, “A Gene Transfer Vector-Cell Line System for Complete Functional Complementation of Adenovirus Early Regions E1 and E4,” Journal of Virology, vol. 70, No. 9, pp. 6497-6501 (Sep. 1996). [cited by applicant]
Fallaux et al, “New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent Adenoviruses,” Human Gene Therapy, vol. 9, pp. 1909-1917 (Sep. 1998). [cited by applicant]
Gao et al, “A Cell Line for High-Yield Production of E1-Deleted Adenovirus Vectors without the Emergence of Replication-Competent Virus,” Human Gene Therapy, vol. 11, pp. 213-219 (Jan. 2000). [cited by applicant]
Goerke et al, “Development of a Novel Adenovirus Purification Process Utilizing Selective Precipitation of Cellular DNA,” Biotechnology and Bioengineering, vol. 91, pp. 12-21 (2005). [cited by applicant]
Havenga et al, “Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells,” Journal of General Virology, vol. 87, pp. 2135-2143 (2006). [cited by applicant]
Hoganson et al, “Development of a Stable Adenoviral Vector Formulation,” BioProcessing Journal, vol. 1, No. 1, pp. 43-48 (Mar. 2002). [cited by applicant]
Kim et al, “Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection,” Vaccine, vol. 28, pp. 38… [cited by applicant]
Kohlmann et al, “Protective Efficacy and Immunology of an Adenoviral Vector Vaccine Encoding the Codon-Optimized F Protein of Respiratory Syncytial Virus,” Journal of Virology, vol. 83, No. 23, pp. 12601-12610 (Dec. 200… [cited by applicant]
Konz et al, “Serotype Specificity of Adenovirus Purification Using Anion-Exchange Chromatography,” Human Gene Therapy, vol. 16, pp. 1346-1353 (Nov. 2005). [cited by applicant]
Konz et al, “Scaleable Purification of Adenovirus Vectors,” Methods in Molecular Biology, vol. 434, No. 2, pp. 13-23 (2008). [cited by applicant]
Krarup et al, “A Highly Stable Prefusion Rsv F Vaccine Derived from Structural Analysis of the Fusion Mechanism,” Nature Communications, vol. 6, pp. 1-11 (Sep. 2015). [cited by applicant]
Nan et al, “Development of an Ad7 cosmid system and generation of an Ad7DeltaE1DeltaE3HIVMN env/rev recombinant virus,” Gene Therapy, vol. 10, pp. 326-336 (2003). [cited by applicant]
Pemberton et al, “Cytoxic T Cell Specificity for Respiratory Syncytial Virus Proteins: Fusion Protein is an Important Target Antigen,” Journal of General Virology, vol. 68, pp. 2177-2182 (1987). [cited by applicant]
Solabomi et al, “The Oligomerization Domain of C4-Binding Protein (C4bp) Acts as an Adjuvant, and the Fusion Protein Comprised of the 19-Kilodalton Merozoite Surface Protein 1 Fused with the Murine C4bp Domain Protects … [cited by applicant]
Vogels et al, “Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity,” Journal of Virology, vol. 77, No. 1… [cited by applicant]
Yu et al, “Single Intranasal Immunization with Recombinant Adenovirus-Based Vaccine Induces Protective Immunity against Respiratory Syncytial Virus Infection,” Journal of Virology, vol. 82, No. 5, pp. 2350-2357 (Mar. 20… [cited by applicant]
Int'l Search Report and Written Opinion issued Jun. 12, 2017 in Int'l Application No. PCT/EP2017/057957. [cited by applicant]
Krause et al, “A Broadly Neutralizing Human Monclonal Antibody That Recognizes a Conserved, Novel Epitope on the Globular Head of the Influenza H1N1 Virus Hemagglutinin,” Journal of Virology, vol. 85, No. 20, pp. 10905-… [cited by applicant]
McLellan et al, “Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes,” Journal of Virology, vol. 85, No. 15, pp. 7788-7796 (Aug. 2011… [cited by applicant]
Database Geneseq (online) “RSV fusion protein N671 S215P, RSV CL57-v224, fibritin, SEQ: 74”, XP002761983, retrieved from EBI accession No. GSP:BBP75438, Database accession No. BBP75438 sequence. [cited by applicant]
U.S. Appl. No. 17/594,394, filed Oct. 14, 2021. Inventor, Benoit Christophe Stephan Callendret. [cited by applicant]
U.S. Appl. No. 17/595,255, filed Nov. 12, 2021. Inventor, Benoit Christophe Stephan Callendret. [cited by applicant]
Anonymous, “History of Changes for Study: NCT03334695,” Dec. 5, 2018, Retrieved from the Internet: URL: https://clincaltrials.gov/ct2/history/NCT03334695?V_8-View#StudyPageTop retrived Jul. 7, 2020. [cited by applicant]
Chen, Xiangpeng, et al. “Genetic variations in the fusion protein of respiratory syncytial virus isolated from children hospitalized with community-acquired pneumonia in China.” Scientific reports 8.1 (2018): 4491. [cited by applicant]
Hause, Anne M., et al. “Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B.” PLoS One 12.4 (2017): e0175792. [cited by applicant]
Williams Kristi et al, “Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine with an Adenovirus 26 Vector Encoding Pre-Fusion F (Ad26.RSV.preF) in adults 60 years and older.”, The Journal of … [cited by applicant]
D. Roymans et al: “Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein”, Proceedings of the National Academy of Sciences, v… [cited by applicant]
Int'l Search Report and Written Opinion dated Dec. 17, 2018 in Int'l Application No. PCT/EP2018/074710. [cited by applicant]
Int'l Search Report and Written Opinion dated Sep. 8, 2018 in Int'l Application No. PCT/EP2018/062604. [cited by applicant]
Int'l Search Report dated Oct. 10, 2016 in Int'l Application No. PCT/EP2016/066104. [cited by applicant]
J. S. Mclellan, M. Chen, S. Leung, K. W. Graepel, X. Du, Y. Yang, T. Zhou, U. Baxa, E. Yasuda, T. Beaumont, A. Kumar, K. Modjarrad, Z. Zheng, M. Zhao, N. Xia, P. D. Kwong, B. S. Graham, “Structure of RSV Fusion Glycopro… [cited by applicant]
Kumaria, Rajni, et al., “Whole genome characterization of non-tissue culture adapted HRSV strains in severely infected children,” Virology Journal, vol. 8 (2011) 13 pages. [cited by applicant]